A CLINICAL STAGE COMPANY WITH A UNIQUE DRUG DEVELOPMENT PLATFORM WHICH CREATES

Established in 2007 with the goal of developing Curcumin for cancer treatment, Signpath has since expanded into the area of cardiology, specifically the mitigation of pharmaceutical cardiac side effects.